Clinical Trial Update: Sintilimab and Anlotinib Combined With Chemotherapy in Neoadjuvant Treatment of Resectable Esophageal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update on neoadjuvant treatment for resectable esophageal cancer using sintilimab and anlotinib in combination with chemotherapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• Sintilimab (sintilimab)

Snippet

Sponsor: Tang-Du Hospital | Conditions: Sintilimab and Anlotinib in Combination With Chemotherapy | Phase 2 | Status: COMPLETED